Argenx Stops Late-Stage Sjogren's Trial of Efgartigimod, Raising Questions on Single-Drug Dependence

On October 8, Argenx announced discontinuation of UNITY, its late-stage trial of efgartigimod in Sjogren's syndrome. The company's shares fell 12% in a single day, and its market value dropped back to $51.2 billion. The article uses the case to discuss the structural fragility of single-product dependence in the autoimmune field.